Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech
January 14, 2020 at 15:12 PM EST
Under the deal, inked in November 2018, NextCure gave Eli Lilly access to its proprietary platform for research aimed at developing and commercializing new cancer therapies.
